Shanghai Pharmaceutical To Focus Fully On Drug Distribution
This article was originally published in PharmAsia News
Shanghai Pharmaceutical Co., Ltd. has announced that it will withdraw from drug R&D and concentrate its resources on drug distribution, a business it has been leading domestically for nine years. The company will transfer its 19.66 percent stake in Shanghai Fudan-Zhangjiang Bio-Pharmaceutical and inject 6.5 million yuan to its holding company Shanghai Waigaoqiao Pharmaceutical Business And Distribution Center. However, Shanghai Pharmaceutical will not give up its original equipment manufacturing business, which gives a return on investment of 27.5 percent. It will renovate Tianping Pharmaceutical Factory's machining workshop to carry out OEM for U.S. Perrigo. (Click here for more - Chinese Language)
You may also be interested in...
Mexico's Genomma Lab recorded strong double-digit growth for its OTC business in the second quarter as sales more than doubled at its US consumer health operation.
New board directors named at Autolus Therapeutics, Beximco Pharmaceuticals, Tetraphase Pharmaceuticals and Vesigen.
After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.